Come visit our booth # Z3 C33 – Discover the power of the PIE and revogene instrument for molecular detection of infectious diseases.
Read the entire Genomeweb interview to learn more on GenePOC’s vision, future SMRT Panels (Specific, Medically
appropriate, Reimbursement appropriate Test) in alignment with the Palmetto decision, and User experience comments on revogene benefits and competitive advantages.
Come visit our booth #1629 – Discover the power of the PIE and revogene instrument for molecular detection of infectious diseases.
Come visit our booth #1204 – Discover the power of the PIE and revogene instrument for molecular detection of infectious diseases.
GenePOC will participate in the ASM (American Society for Microbiology) from June 7 to 11, in Atlanta, USA.
Come visit our booth #1420 – Discover the power of the PIE and revogene instrument for molecular detection of infectious diseases.
Practical Patient Care talks to Dr Mayra Bermudez Martinez, an obstetrician in the Klinik für Gynäkologie und Geburtshilfe at the Hochst Klinikum in Frankfurt, about the importance of timely screening for Group B Streptococcus in infants.
Read the entire article here.
GenePOC will participate in the 28th ECCMID (European Congress of Clinical Microbiology and Infectious Diseases) from April 21 to 24, in Madrid, Spain.
Come visit our booth #40 – Discover the power of the PIE and revogene instrument for molecular detection of infectious diseases.
Don’t miss our symposium on Monday 23rd – Hall J – 9 to 11 am.
Under the terms of the services agreement, Primerdesign will develop a triplex molecular diagnostic assay to identify influenza A, influenza B and respiratory syncytial virus A and B (RSV A and B) which will subsequently be run on GenePOC’s revogene™ instrument.
Full article : here
Clostridium difficile infection (CDI) is the main cause of infectious antibiotic-associated diarrhea with approximately 500,000 infections and $4.8 billion in excess healthcare cost per year in the US1. While diagnosis of C. difficile still remains controversial worldwide, the new IDSA guidelines reaffirm that PCR is the most sensitive method for toxigenic C. difficile detection. Find here the GenePOC highlights.
In our commitment to help healthcare institutions to manage CDI appropriately, we provide a timely and sensitive solution, as well as the support to help build pre-agreed testing criteria for the detection of C. difficile in symptomatic patients.
Read the full IDSA Guidelines: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/cix1085/4855916
Ref 1: https://www.cdc.gov/media/releases/2015/p0225-clostridium-difficile.html
Contact UsIf you have questions, comments or need more information concerning GenePOC, talk to one of our customer service representatives. We will be pleased to assist you.
Write360 Rue Franquet, Porte 3
Canada G1P 4N3
Call1 (418) 650-3535
Monday to Friday
8:00 a.m. to 5:00 p.m. EST